博济医药：司美格鲁肽注射液研发项目进展顺利

Group 1 - The core point of the article is the progress of the development of semaglutide injection, which is being developed by a company in collaboration with another firm, and the timeline for submitting the market application remains undisclosed due to commercial confidentiality [2]. Group 2 - The company, Boji Pharmaceutical (300404.SZ), confirmed that it is providing phase III clinical research services for the semaglutide injection project, which targets both diabetes and weight loss indications [2]. - The project is reported to be progressing smoothly, although specific details about the timeline cannot be disclosed [2].